Cronos Group Inc. 10-Q

Item 1. Financial Statements Table of Contents Condensed Consolidated Balance Sheets as of March 3 1 , 202 4 (Unaudited) and December 31, 202 3 4 Condensed Consolidated Statements of Net Loss and Comprehensive Loss for the three months ended March 3 1 , 202 4 and 202 3 (Unaudited) 5 Condensed Consolidated Statements of Changes in Equity for the three months ended March 3 1 , 202 4 and 202 3 (Unaudited) 6 Condensed Consolidated Statements of Cash Flows for the three months ended March 3 1 , 202 4 and 202 3 (Unaudited) 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8 3 Cronos Group Inc. Condensed Consolidated Balance Sheets (In thousands of U.S. dollars, except share amounts, unaudited) Table of Contents As of March 31, 2024 As of December 31, 2023 Assets Current assets Cash and cash equivalents $ 855,114 $ 669,291 Short-term investments — 192,237 Accounts receivable, net 15,336 13,984 Interest receivable 3,864 10,012 Other receivables 5,919 6,341 Current portion of loans receivable, net 5,668 5,541 Inventory, net 30,639 30,495 Prepaids and other current assets 6,278 5,405 Held-for-sale assets 19,398 — Total current assets 942,216 933,306 Equity method investments, net 20,521 19,488 Other investments 19,758 35,251 Non-current portion of loans receivable, net 66,545 69,036 Property, plant and equipment, net 37,171 59,468 Right-of-use assets 1,213 1,356 Goodwill 1,035 1,057 Intangible assets, net 20,018 21,078 Other assets 58 45 Total assets $ 1,108,535 $ 1,140,085 Liabilities Current liabilities Accounts payable $ 9,401 $ 12,130 Income taxes payable 73 64 Accrued liabilities 22,503 27,736 Current portion of lease obligation 958 994 Derivative liabilities 118 102 Current portion due to non-controlling interests 366 373 Total current liabilities 33,419 41,399 Non-current portion due to non-controlling interests 1,033 1,003 Non-current portion of lease obligation 1,305 1,559 Total liabilities 35,757 43,961 Shareholders’ equity Share capital (authorized for issue as of March 31, 2024 and December 31, 2023: unlimited; shares outstanding as of March 31, 2024 and December 31, 2023: 382,011,178 and 381,298,853 , respectively) 615,625 613,725 Additional paid-in capital 48,048 48,449 Retained earnings 414,478 416,719 Accumulated other comprehensive gain (loss) ( 1,793 ) 20,678 Total equity attributable to shareholders of Cronos Group 1,076,358 1,099,571 Non-controlling interests ( 3,580 ) ( 3,447 ) Total shareholders’ equity 1,072,778 1,096,124 Total liabilities and shareholders’ equity $ 1,108,535 $ 1,140,085 See notes to condensed consolidated interim financial statements. 4 Cronos Group Inc. Condensed Consolidated Statements of Net Loss and Comprehensive Loss (In thousands of U.S dollars, except share and per share amounts, unaudited) Table of Contents Three months ended March 31, 2024 2023 Net revenue, before excise taxes $ 35,367 $ 26,554 Excise taxes ( 10,079 ) ( 7,059 ) Net revenue 25,288 19,495 Cost of sales 20,805 16,568 Gross profit 4,483 2,927 Operating expenses Sales and marketing 5,332 5,741 Research and development 997 2,039 General and administrative 8,907 11,856 Restructuring costs 83 — Share-based compensation 2,015 2,535 Depreciation and amortization 1,123 1,525 Impairment loss on long-lived assets 1,974 — Total operating expenses 20,431 23,696 Operating loss ( 15,948 ) ( 20,769 ) Other income Interest income, net 14,245 11,175 Loss on revaluation of derivative liabilities ( 18 ) ( 65 ) Share of income (loss) from equity method investments 1,448 ( 496 ) Loss on revaluation of financial instruments ( 2,642 ) ( 7,758 ) Impairment loss on other investments ( 12,734 ) — Foreign currency transaction gain (loss) 13,259 ( 1,643 ) Other, net ( 652 ) 85 Total other income 12,906 1,298 Loss before income taxes ( 3,042 ) ( 19,471 ) Income tax benefit ( 558 ) ( 1,436 ) Loss from continuing operations ( 2,484 ) ( 18,035 ) Loss from discontinued operations — ( 1,222 ) Net loss ( 2,484 ) ( 19,257 ) Net loss attributable to non-controlling interest ( 243 ) ( 88 ) Net loss attributable to Cronos Group $ ( 2,241 ) $ ( 19,169 ) Comprehensive loss Net loss $ ( 2,484 ) $ ( 19,257 ) Other comprehensive income (loss) Foreign exchange gain (loss) on translation ( 22,361 ) 2,414 Comprehensive loss ( 24,845 ) ( 16,843 ) Comprehensive loss attributable to non-controlling interests ( 133 ) ( 8 ) Comprehensive loss attributable to Cronos Group $ ( 24,712 ) $ ( 16,835 ) Net loss per share Basic and diluted - continuing operations $ ( 0.01 ) $ ( 0.05 ) Basic and diluted - discontinued operations — — Basic and diluted - total $ ( 0.01 ) $ ( 0.05 ) See notes to condensed consolidated interim financial statements. 5 Cronos Group Inc. Condensed Consolidated Statements of Changes in Equity For the three months ended March 31, 2024 and 2023 (In thousands of U.S. dollars, except share amounts, unaudited) Number of shares Share capital Additional paid-in capital Retained earnings Accumulated other comprehensive income (loss) Non-controlling interests Total shareholders’ equity Balance as of January 1, 2024 381,298,853 $ 613,725 $ 48,449 $ 416,719 $ 20,678 $ ( 3,447 ) $ 1,096,124 Activities relating to share-based compensation 712,325 1,900 ( 401 ) — — — 1,499 Net income (loss) — — — ( 2,241 ) — ( 243 ) ( 2,484 ) Foreign exchange gain on translation — — — — ( 22,471 ) 110 ( 22,361 ) Balance as of March 31, 2024 382,011,178 $ 615,625 $ 48,048 $ 414,478 $ ( 1,793 ) $ ( 3,580 ) $ 1,072,778 Number of shares Share capital Additional paid-in capital Retained earnings Accumulated other comprehensive income (loss) Non-controlling interests Total shareholders’ equity Balance as of January 1, 2023 380,575,403 $ 611,318 $ 42,682 $ 490,682 $ ( 797 ) $ ( 2,921 ) $ 1,140,964 Activities relating to share-based compensation 240,518 917 1,362 — — — 2,279 Net loss — — — ( 19,169 ) — ( 88 ) ( 19,257 ) Foreign exchange gain on translation — — — — 2,334 80 2,414 Balance as of March 31, 2023 380,815,921 $ 612,235 $ 44,044 $ 471,513 $ 1,537 $ ( 2,929 ) $ 1,126,400 See notes to condensed consolidated interim financial statements. 6 Cronos Group Inc. Condensed Consolidated Statements of Cash Flows (In thousands of U.S. dollars, except share amounts, unaudited) Table of Contents Three months ended March 31, 2024 2023 Operating activities Net loss $ ( 2,484 ) $ ( 19,257 ) Adjustments to reconcile net loss to cash used in operating activities: Share-based compensation 2,015 2,551 Depreciation and amortization 1,731 2,405 Impairment loss on long-lived assets 1,974 — Impairment loss on other investments 12,734 — Loss from investments 894 8,419 Loss on revaluation of derivative liabilities 18 65 Changes in expected credit losses on long-term financial assets ( 191 ) ( 764 ) Foreign currency transaction (gain) loss ( 13,259 ) 1,643 Other non-cash operating activities, net 1,066 ( 2,850 ) Changes in operating assets and liabilities: Accounts receivable, net ( 1,654 ) 8,201 Interest receivable 4,251 ( 1,953 ) Other receivables 289 671 Prepaids and other current assets ( 985 ) ( 848 ) Inventory ( 777 ) ( 6,824 ) Accounts payable ( 2,775 ) 1,555 Income taxes payable 11 ( 32,813 ) Accrued liabilities ( 5,062 ) ( 7,894 ) Cash flows used in operating activities ( 2,204 ) ( 47,693 ) Investing activities Purchase of short-term investments — ( 422,612 ) Proceeds from short-term investments 188,872 113,355 Proceeds from repayment on loan receivables 2,678 6,249 Purchase of property, plant and equipment ( 1,724 ) ( 804 ) Purchase of intangible assets ( 270 ) — Cash flows provided by (used in) investing activities 189,556 ( 303,812 ) Financing activities Withholding taxes paid on share-based awards ( 645 ) ( 743 ) Cash flows used in financing activities ( 645 ) ( 743 ) Effect of foreign currency translation on cash and cash equivalents ( 884 ) 1,271 Net change in cash and cash equivalents 185,823 ( 350,977 ) Cash and cash equivalents, beginning of period 669,291 764,644 Cash and cash equivalents, end of period $ 855,114 $ 413,667 Supplemental cash flow information Interest paid $ — $ — Interest received $ 14,641 $ 7,558 Income taxes paid $ 579 $ 32,932 See notes to condensed consolidated interim financial statements. 7 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents 1. Background, Basis of Presentation, and Summary of Significant Accounting Policies (a) Background Cronos Group Inc. (“Cronos” or the “Company”) is incorporated in the province of British Columbia under the Business Corporations Act (British Columbia) with principal executive offices at 111 Peter St., Suite 300, Toronto, Ontario, M5V 2H1. The Company’s common shares are listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.” Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach ® , PEACE NATURALS ® and Lord Jones ® . (b) Basis of presentation These condensed consolidated interim financial statements of Cronos are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”). Certain prior period amounts have been reclassified to conform to the current year presentation of our condensed consolidated interim financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity. (c) Discontinued Operations In the second quarter of 2023, the Company exited its U.S. hemp-derived cannabinoid product operations. The exit of the U.S. operations represented a strategic shift that has a major effect on the Company’s operations and financial results, and as such, qualifies for reporting as discontinued operations in our condensed consolidated statements of net loss and comprehensive loss. Prior period amounts have been reclassified to reflect the discontinued operations classification of the U.S. operations. For more information, see Note 2 “ Discontinued Operations ”. (d) Segment information Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. Prior to the second quarter of 2023, the Company reported results for two reportable segments, the U.S. and Rest of World. In the second quarter of 2023, as a result of the Company’s exit of its then-existing U.S. operations, the Company determined that it has one operating segment and therefore one reportable segment, which is comprised of operations in Canada and Israel and is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets . All prior period segment disclosure information has been reclassified to conform to the current reporting structure in this Form 10-Q. These reclassifications had no effect on our consolidated financial statements in any period presented. (e) Revenue recognition The following tables present the Company’s revenue by major product category for continuing operations: Three months ended March 31, 2024 2023 Cannabis flower $ 17,525 $ 13,128 Cannabis extracts 7,727 6,301 Other 36 66 Net revenue $ 25,288 $ 19,495 8 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents Net revenue attributed to a geographic region based on the location of the customer were as follows for continuing operations: Three months ended March 31, 2024 2023 Canada $ 18,871 $ 14,434 Israel 6,417 5,061 Net revenue $ 25,288 $ 19,495 (f) Concentration of risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments and loans receivable. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $ 952,446 and $ 966,442 as of March 31, 2024 and December 31, 2023, respectively. An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of March 31, 2024 and December 31, 2023, the Company had $ 15 and $ 3 , respectively, in expected credit losses that have been recognized on receivables from contracts with customers. As of March 31, 2024, the Company assessed that there is a concentration of credit risk, as 40 % of the Company’s accounts receivable were due from two customers with an established credit history with the Company. As of December 31, 2023, 37 % of the Company’s accounts receivable were due from one customer with an established credit history with the Company. The Company sells products to a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenue. During the three months ended March 31, 2024, the Company earned a total net revenue before excise taxes of $ 21,866 from three major customers, together accounting for 62 % of the Company’s total net revenues before excise taxes. During the three months ended March 31, 2023, the Company earned a total net revenue before excise taxes of $ 15,168 from two major customers, together accounting for 56 % of the Company’s total net revenues before excise taxes. (g) New accounting pronouncements not yet adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information on the CODM and disclosures for entities with a single reportable segment. Additionally, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and we expect to adopt ASU 2023-07 retrospectively. The Company does not expect the adoption of ASU 2023-07 to have a material impact on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 enhances the existing income tax disclosures to provide additional information to better assess how an entity’s operations, related tax risks and tax planning, and operational opportunities affect its tax rate and prospects for future cash flows. ASU 2023-09 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and we expect to adopt ASU 2023-09 prospectively. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its consolidated financial statements. 9 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents (h) Adoption of new accounting pronouncements On January 1, 2024, the Company adopted ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. The adoption of ASU 2022-03 did not have a material impact on the Company’s condensed consolidated interim financial statements. With respect to the adoption of ASU 2022-03, see Note 4 “Investments” for discussion of the contractual restrictions related to the PharmaCann Option (as defined below). 2. Discontinued Operations In the second quarter of 2023, the Company exited its then-existing U.S. hemp-derived cannabinoid product operations. Accordingly, the net loss of the U.S. operations for the three months ended March 31, 2023 are reported separately as loss from discontinued operations on the condensed consolidated statements of net loss and comprehensive loss. There was no activity in discontinued operations for the three months ended March 31, 2024. The following table presents the major components comprising loss from discontinued operations in the condensed consolidated statements of operations for the three months ended March 31, 2023: Three months ended March 31, 2023 Net revenue $ 649 Cost of sales 1,196 Gross profit ( 547 ) Operating expenses Sales and marketing 131 Research and development 2 General and administrative 523 Share-based compensation 16 Depreciation and amortization 8 Total operating expenses 680 Interest income 5 Total other income (loss) 5 Loss before income taxes ( 1,222 ) Income tax expense (benefit) — Net loss from discontinued operations $ ( 1,222 ) The following tables present the Company’s discontinued operations revenue by major product category: Three months ended March 31, 2023 Cannabis extracts 649 Net revenue $ 649 The Company had no assets or liabilities presented in the condensed consolidated balance sheets related to its discontinued operations as of both March 31, 2024 and December 31, 2023. For the three months ended March 31, 2024, there were no purchases of property plant and equipment related to discontinued operations. For the three months ended March 31, 2023, purchases of property plant and equipment related to discontinued operations were $ 67 . 10 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents 3. Inventory, net Inventory, net is comprised of the following items: As of March 31, 2024 As of December 31, 2023 Raw materials $ 3,486 $ 4,795 Work-in-progress 11,423 10,593 Finished goods 15,406 14,819 Supplies and consumables 324 288 Total $ 30,639 $ 30,495 4. Investments (a) Equity method investments, net A reconciliation of the carrying amount of the investments in equity method investees, net is as follows: Ownership interest As of March 31, 2024 As of December 31, 2023 Cronos Growing Company Inc. (“Cronos GrowCo”) 50 % $ 20,521 $ 19,488 $ 20,521 $ 19,488 The following is a summary of the Company’s share of net income (losses) from equity investments accounted for under the equity method of accounting: For the three months ended March 31, 2024 2023 Cronos GrowCo $ 1,448 $ ( 496 ) $ 1,448 $ ( 496 ) (b) Other investments Other investments consist of investments in common shares and options of two companies in the cannabis industry. PharmaCann Option On June 14, 2021, the Company purchased an option (the “PharmaCann Option”) to acquire 473,787 shares of Class A Common Stock of PharmaCann, Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, at an exercise price of $ 0.0001 per share, representing approximately 10.5 % of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $ 110,392 . The PharmaCann Option is classified as an investment in an equity security without a readily determinable fair value. The Company measures the PharmaCann Option at cost less accumulated impairment charges, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. As of March 31, 2024 and December 31, 2023, based on updated information provided by PharmaCann in the first quarter, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 6.3 % and 6.6 %, respectively. The decrease in the Company’s ownership percentage since acquisition does not materially affect the Company’s rights under the PharmaCann Option. The PharmaCann Option is measured at fair value on a non-recurring basis and is a level 3 asset. See Note 10 “Fair Value Measurements” for more information on the fair value hierarchy. The PharmaCann Option is reported as Other investments on the consolidated balance sheet for the periods ended March 31, 2024 and December 31, 2023. During the first quarter of 2024, the Company identified adverse forecast changes in the financial performance of PharmaCann as an indicator of impairment related to the PharmaCann Option and conducted an analysis comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using the market approach. Under the market approach, the key assumptions are the selected multiples and the discount for lack of marketability. As a result of this analysis, the Company recorded a non-cash impairment charge of $ 12,734 in the first quarter of 2024 as the difference between the carrying amount of the PharmaCann Option and its estimated fair value, in the condensed consolidated statements of net loss and comprehensive loss for the three months ended March 31, 2024. 11 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents The Company may sell, transfer or dispose of the PharmaCann Option without PharmaCann’s prior written consent, subject to the following conditions: (i) any transferee of any part of the PharmaCann Option must comply with and commit to comply with all regulations issued by a governmental entity applicable to such transferee in all material respects; (ii) any transferee of any part of the PharmaCann Option must agree to be bound by the terms of the Option Purchase Agreement, dated as of June 14, 2021 (the “Option Purchase Agreement”), as a “Purchaser” thereunder; (iii) the Company may not split and/or transfer the PharmaCann Option, in the aggregate, to more than four persons (with certain exceptions); (iv) no transferee may be a Prohibited Assignee (as defined in the Option Purchase Agreement); and (v) subject to certain exceptions, in the event that the Company (or a Permitted Transferee of the whole PharmaCann Option) transfers less than all of the PharmaCann Option to any third party that is not a Permitted Transferee, certain governance and information rights terminate immediately, unless waived by the PharmaCann board of directors in its sole and absolute discretion. Additionally, in the event of an initial underwritten public offering of PharmaCann’s common stock pursuant to an effective registration statement, to the extent that holders of PharmaCann common stock are subject to any lock-up period imposed by the underwriter in connection therewith, the Company will, if applicable, execute a customary lock-up agreement on the same material terms and conditions as the other holders of common stock are subject to or as otherwise agreed between PharmaCann and the Company, subject to certain conditions with respect to the duration of the lock-up period. Vitura Health Limited (formerly known as Cronos Australia) The Company owns approximately 10 % of the outstanding common shares of Vitura Health Limited (“Vitura”). The investment is considered an equity security with a readily determinable fair value. Changes in the fair value of the investment are recorded as gain (loss) on revaluation of financial instruments on the condensed consolidated statements of net loss and comprehensive loss. The following table summarizes the Company’s other investments activity: As of January 1, 2024 Unrealized loss Impairment charges Foreign exchange effect As of March 31, 2024 PharmaCann $ 25,650 $ — $ ( 12,734 ) $ — $ 12,916 Vitura 9,601 ( 2,342 ) — ( 417 ) 6,842 $ 35,251 $ ( 2,342 ) $ ( 12,734 ) $ ( 417 ) $ 19,758 As of January 1, 2023 Unrealized loss Impairment charges Foreign exchange effect As of March 31, 2023 PharmaCann $ 49,000 $ — $ — $ — $ 49,000 Vitura 21,993 ( 7,923 ) — ( 237 ) 13,833 $ 70,993 $ ( 7,923 ) $ — $ ( 237 ) $ 62,833 12 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents 5. Loans Receivable, net Loans receivable, net consists of the following: As of March 31, 2024 As of December 31, 2023 GrowCo Credit Facility $ 4,927 $ 5,034 Add: Current portion of accrued interest 741 507 Total current portion of loans receivable 5,668 5,541 GrowCo Credit Facility 51,459 53,638 Mucci Promissory Note 13,092 13,379 Cannasoul Collaboration Loan 1,732 1,771 Add: Long-term portion of accrued interest 262 248 Total long-term portion of loans receivable 66,545 69,036 Total loans receivable, net $ 72,213 $ 74,577 Cronos GrowCo Credit Facility On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C$ 100,000 (the “GrowCo Credit Facility”). The GrowCo Credit Facility is secured by substantially all present and after-acquired personal and real property of Cronos GrowCo. In August 2021, the GrowCo Credit Facility was amended to increase the aggregate principal amount available to C$ 105,000 . As of both March 31, 2024, and December 31, 2023, Cronos GrowCo had drawn C$ 104,000 ($ 76,855 and $ 78,532 , respectively) from the GrowCo Credit Facility. The interest rate on the outstanding borrowings is the Canadian Prime Rate plus 1.25 %, with interest payments due in December 2021, December 2022, and quarterly thereafter. Principal payments of C$ 1,000 commenced in March 2022 and are currently C$ 1,667 , due quarterly. For the three months ended March 31, 2024, Cronos GrowCo repaid C$ 1,667 ($ 1,231 ) in principal and C$ 1,943 ($ 1,435 ) in interest related to the GrowCo Credit Facility. As of March 31, 2024, Cronos GrowCo had repaid an aggregate C$ 13,167 ($ 9,730 ) and C$ 22,464 ($ 16,601 ) in principal and interest, respectively, under the terms of the GrowCo Credit Facility. Mucci Promissory Note On June 28, 2019, the Company entered into a promissory note receivable agreement (the “Mucci Promissory Note”) for C$ 16,350 (approximately $ 12,082 ) with the Cronos GrowCo joint venture partner (“Mucci”). The Mucci Promissory Note is secured by a general security agreement covering all the assets of Mucci. On September 30, 2022, the Mucci Promissory Note was amended and restated to increase the interest rate from 3.95 % to the Canadian Prime Rate plus 1.25 %, change the interest payments from quarterly to annual, and defer Mucci’s initial cash interest payment from September 30, 2022 to July 1, 2023. Prior to July 1, 2022, interest accrued on the Mucci Promissory Note was capitalized as part of the principal balance. As of July 1, 2022, interest was accrued and to be paid in cash beginning on July 1, 2023. Prior to 2023, there were no repayments of principal or interest on the Mucci Promissory Note. For the three months ended March 31, 2024 and 2023, there were no repayments of principal or interest on the Mucci Promissory Note. Cannasoul Collaboration Loan As of both March 31, 2024 and December 31, 2023, Cannasoul Lab Services Ltd. has received ILS 8,297 (approximately $ 2,249 and $ 2,294 , respectively), from the Cannasoul Collaboration Loan. 13 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents Expected credit loss allowances on the Company’s long-term financial assets for the three months ended March 31, 2024 and 2023 were comprised of the following items: As of January 1, 2024 Increase (decrease) (i) Foreign exchange effect As of March 31, 2024 GrowCo Credit Facility $ 11,176 $ ( 197 ) $ ( 239 ) $ 10,740 Mucci Promissory Note 89 2 ( 2 ) 89 Cannasoul Collaboration Loan 524 4 ( 10 ) 518 $ 11,789 $ ( 191 ) $ ( 251 ) $ 11,347 As of January 1, 2023 Increase (decrease) Foreign exchange effect As of March 31, 2023 GrowCo Credit Facility $ 12,455 $ ( 770 ) $ 34 $ 11,719 Mucci Promissory Note 89 2 — 91 Cannasoul Collaboration Loan 522 4 ( 12 ) 514 $ 13,066 $ ( 764 ) $ 22 $ 12,324 (i) During the three and months ended March 31, 2024, $ 191 was recorded as a decrease to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive loss as a result of principal and interest payments made by Cronos GrowCo reducing our expected credit losses on loans receivable. During the three months ended March 31, 2023, $ 764 was recorded as a decrease to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive loss as a result of adjustments to our expected credit losses. 6. Restructuring In the first quarter of 2022, the Company initiated a strategic plan to realign the business around its brands, centralize functions and evaluate the Company’s supply chain (the “Realignment”). As part of the Realignment, on February 28, 2022, the Board approved plans to leverage the Company’s strategic partnerships to improve supply chain efficiencies and reduce manufacturing overhead by exiting its production facility in Stayner, Ontario, Canada (the “Peace Naturals Campus”). On February 27, 2023, the Board approved revisions to the Realignment, which are expected to result in the Company maintaining select components of its operations at the Peace Naturals Campus, namely distribution warehousing, certain research and development activities and manufacturing of certain of the Company’s products, while seeking to sell and lease back all or some of the Peace Naturals Campus or to lease certain portions of the Peace Naturals Campus to third parties. In the third quarter of 2023, the Board approved revisions to the Realignment to wind-down operations at its Winnipeg, Manitoba facility (“Cronos Fermentation”), list the Cronos Fermentation facility for sale, and implement additional organization-wide cost reductions as the Company continues its Realignment initiatives. The Realignment initiatives were intended to position the Company to drive profitable and sustainable growth over time. During the first quarter of 2024, the Company ceased operations at Cronos Fermentation and performed an assessment under ASC 360 of the recoverability of the carrying value of the Cronos Fermentation assets, and determined the carrying value of the assets was not fully recoverable. The fair value was estimated using a combination of the market and income approaches. As a result of this analysis, an impairment loss on long-lived assets of $ 1,631 was recorded to the condensed consolidated statements of net loss and comprehensive loss in the three months ended March 31, 2024. As of March 31, 2024, the assets of Cronos Fermentation met the held-for-sale criteria and were reclassified to assets held for sale on the condensed consolidated balance sheet and the assets were valued at their fair value less costs to sell. A $ 445 loss for estimated costs to sell was recorded as a result of the classification of the Cronos Fermentation assets as held for sale. During the three months ended March 31, 2024, the Company incurred $ 83 of restructuring costs in its continuing operations in connection with the Realignment. Charges related thereto include employee-related costs such as severance and other termination benefits, as well as other related costs. During the three months ended March 31, 2023, the Company recognized no restructuring costs in continuing operations in connection with the Realignment. 14 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents The following table summarizes the Company’s restructuring activity for the three months ended March 31, 2024 and 2023: Accrual as of January 1, 2024 Expenses Payments/Write-offs Accrual as of March 31, 2024 Employee Termination Benefits $ 150 $ 62 $ ( 174 ) $ 38 Other Restructuring Costs — 21 ( 21 ) — Total $ 150 $ 83 $ ( 195 ) $ 38 Accrual as of January 1, 2023 Expenses Payments/Write-offs Accrual as of March 31, 2023 Employee Termination Benefits $ 403 $ — $ ( 295 ) $ 108 Other Restructuring Costs 21 — ( 21 ) — Total $ 424 $ — $ ( 316 ) $ 108 7. Share-based Compensation (a) Share-based award plans The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan”), the Employment Inducement Award Plan #1 (the “Employment Inducement Award Plan”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU Plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the 2018 Stock Option Plan or the Employment Inducement Award Plan. The following table summarizes the total share-based compensation expense associated with the Company’s stock options and RSUs for the three months ended March 31, 2024 and 2023: For the three months ended March 31, 2024 2023 Stock options $ 34 $ 734 RSUs 1,981 1,801 Total share-based compensation $ 2,015 $ 2,535 (b) Stock options Vesting conditions for grants of options are determined by the Compensation Committee of the Company’s Board of Directors. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three to five years with a maximum term of ten years . The typical vesting for stock option grants made under the 2018 Stock Option Plan is quarterly vesting over three to five years with a maximum term of seven years . The 2018 Stock Option Plan did not, and the 2020 Omnibus Plan does not, authorize grants of options with an exercise price below fair market value. The following is a summary of the changes in stock options for the three months ended March 31, 2024 and 2023: Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2024 $ 14.50 2,103,201 1.84 Cancellation, forfeiture and expiry of options 23.93 ( 9,501 ) Balance as of March 31, 2024 $ 14.46 2,093,700 1.59 Exercisable as of March 31, 2024 $ 15.72 1,874,123 1.10 15 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2023 $ 10.57 5,350,600 0.73 Issuance of options 2.96 188,317 Cancellation, forfeiture and expiry of options 9.05 ( 335,091 ) Balance as of March 31, 2023 $ 10.40 5,203,826 0.75 Exercisable as of March 31, 2023 $ 11.88 3,624,498 0.48 (i) The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. The following table summarizes stock options outstanding: As of March 31, 2024 As of December 31, 2023 2020 Omnibus Plan 702,264 702,264 2018 Stock Option Plan 1,391,436 1,400,937 Total stock options outstanding 2,093,700 2,103,201 (c) Restricted share units The following is a summary of the changes in RSUs for the three months ended March 31, 2024 and 2023: Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2024 $ 3.77 7,381,541 Granted (i) 2.66 1,910,756 Vested and issued 3.52 ( 967,016 ) Cancellation and forfeitures 2.95 ( 65,662 ) Balance as of March 31, 2024 $ 3.55 8,259,619 Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2023 $ 4.63 5,725,470 Granted (i) 2.74 1,927,487 Vested and issued 4.98 ( 345,433 ) Cancellation and forfeitures 4.19 ( 70,108 ) Balance as of March 31, 2023 $ 4.11 7,237,416 (i) RSUs granted in the period vest annually in equal installments over a three-year period from either the grant date or after a three or five year “cliff-period.” All RSUs are subject to such holder’s continued employment through each vesting date. The vesting of such RSUs is not subject to the achievement of any performance criteria. (ii) The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance. (d) Deferred share units The following is a summary of the changes in DSUs for the three months ended March 31, 2024 and 2023: Financial liability Number of DSUs Balance as of January 1, 2024 $ 1,092 521,679 Loss on revaluation 277 — Balance as of March 31, 2024 $ 1,369 521,679 Financial liability Number of DSUs Balance as of January 1, 2023 $ 674 265,732 Gain on revaluation ( 163 ) — Balance as of March 31, 2023 $ 511 265,732 16 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents 8. Loss per Share Basic and diluted loss per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts): Three months ended March 31, 2024 2023 Basic loss per share computation Net loss from continuing operations attributable to the shareholders of Cronos Group $ ( 2,241 ) $ ( 19,169 ) Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share (i) 381,442,597 380,634,208 Basic loss from continuing operations per share $ ( 0.01 ) $ ( 0.05 ) Diluted loss per share from continuing operations $ ( 0.01 ) $ ( 0.05 ) Loss from discontinued operations attributable to the shareholders of Cronos Group $ — $ ( 1,222 ) Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share (i) 381,442,597 380,634,208 Basic loss from discontinued operations per share $ — $ — Diluted loss from discontinued operations per share $ — $ — (i) In computing diluted loss per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive. For the three months ended March 31, 2024 and 2023, total securities of 24,580,665 and 30,086,428 , respectively, were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive. 9. Commitments and Contingencies (a) Commitments There have been no material changes in the information regarding commitments as disclosed in the Company’s Annual Report. (b) Contingencies The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its financial condition but could be material to its results of operations for a quarterly period depending, in part, on its results for that quarter. (i) Class action complaints relating to restatement of 2019 interim financial statements On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its Chief Executive Officer and former Chief Financial Officer. The court consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5, promulgated thereunder, against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenues and internal controls were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board of Directors’ review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. The defendants moved to dismiss on February 8, 2021. On November 17, 2023, the court entered an order granting the motion and dismissed the case with prejudice. On December 1, 2023, the shareholder plaintiffs sought reconsideration of the dismissal, requesting that the court instead dismiss the action without prejudice and permit the plaintiffs to seek leave to further amend the complaint. The reconsideration motion is pending. 17 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim named (i) the Company, (ii) its Chief Executive Officer, (iii) former Chief Financial Officer, (iv) former Chief Financial Officer and Chief Commercial Officer, and (v) current and former members of the Board as defendants and alleged breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleged that certain of the Company’s prior public statements about revenues and internal controls were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board of Directors was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim did not quantify a damage request. On June 28, 2021, the Court dismissed motions brought by the plaintiff for leave to commence a claim for misrepresentation under the Ontario Securities Act and for certification of the action as a class action. The plaintiff appealed the Court’s dismissal of the motions only with respect to the Company, the Chief Executive Officer, and the now former Chief Financial Officer; the remaining defendants were dismissed from the matter with prejudice and the Company and all individual defendants agreed not to seek costs from plaintiff in connection with the dismissal of the motions. On September 26, 2022, the Court of Appeal for Ontario reversed the Superior Court’s dismissal of the leave and certification motions, granted the plaintiff leave to proceed to bring a claim for misrepresentation under the Ontario Securities Act, and remitted the certification motion back to the Superior Court. On April 11, 2023, the plaintiff filed a Fresh as Amended Statement of Claim, which reflected the dismissal of the defendants for which an appeal was not sought, the removal of the claims for oppression under the Ontario Business Corporations Act and common law misrepresentation, as well as shortening the proposed class period. On October 10, 2023, the Superior Court certified the action on behalf of a class of persons or entities who acquired shares in the secondary market, including on the TSX and Nasdaq, during the period from May 9, 2019 to March 30, 2020, other than certain excluded persons. (ii) Regulatory reviews relating to restatements On October 24, 2022, the Company announced regulatory settlements as follows: SEC Settlement On October 24, 2022, the SEC issued an Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8(a) of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21(c) of the Exchange Act, Making Findings, and Imposing a Cease-and-Desist Order (the “Settlement Order”) resolving the Restatements. The Company agreed to settle with the SEC, without admitting or denying the allegations described in the Settlement Order. The Settlement Order fully and finally disposed of the investigation of the Company by the SEC into the Restatements without the payment of any civil penalty or other amount. The Settlement Order required the Company to cease and desist from committing or causing any violations and any future violations of Section 17(a) of the Securities Act, Sections 10(b), 13(a), 13(b)(2)(B) of the Exchange Act and Rules 10b-5, 13a-13, 13a-15(a), 13a-16 and 12b-20 thereunder. As a result of the Settlement Order, the Company (i) lost its status as a well-known seasoned issuer for a period of three years, (ii) is unable to rely on the private offering exemptions provided by Regulations A and D under the Securities Act for a period of five years and (iii) is unable to rely on the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 for a period of three years. OSC Settlement On October 24, 2022, the Ontario Capital Markets Tribunal approved a settlement agreement (the “Settlement Agreement”) between the Company and the staff of the Ontario Securities Commission (the “OSC”), resolving the Restatements. Pursuant to the terms of the Settlement Agreement, which fully and finally disposed the investigation of the Company by the OSC, Cronos agreed to pay a total of C$ 1.34 million to fully settle the matter, and acknowledged that it had failed to comply with the requirement under Section 77 of the Ontario Securities Act to file interim financial reports in the manner set out therein and had acted in a manner contrary to the public interest. 18 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents (iii) Litigation and regulatory inquiries relating to marketing, distribution, import and sale of products On April 17, 2023, a group of plaintiffs led by the Green Leaf (Ale Yarok) political party filed a Statement of Claim and Request for Approval of a Class Action on behalf of a purported class of Israeli cannabis consumers in the District Court of Tel Aviv, Israel, against 26 cannabis-related parties, including three Cronos Israel entities. The Statement of Claim alleges that the defendants violated certain laws relating to the marketing of medical cannabis products, including marketing to unlicensed cannabis consumers. The lawsuit seeks a total of ILS 420 million. The Cronos Israel defendants moved to dismiss the action on August 13, 2023. On January 18, 2024, the Company was notified that the Trade Levies Commissioner of the Israel Ministry of Economy and Industry initiated a public investigation of alleged dumping of medical cannabis imports from Canada into Israel. The Company is responding to requests for information from the Ministry. The Company cannot predict the outcome of the investigation. We expect litigation and regulatory proceedings relating to the marketing, distribution, import and sale of our products to increase. 10. Fair Value Measurements The Company complies with ASC 820 Fair Value Measurements for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by: • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. • Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: March 31, 2024 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 855,114 $ — $ — $ 855,114 Other investments (i) 6,842 — — 6,842 Derivative liabilities — — 118 118 December 31, 2023 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 669,291 $ — $ — $ 669,291 Short-term investments 192,237 — — 192,237 Other investments (i) 9,601 — — 9,601 Derivative liabilities — — 102 102 (i) As of March 31, 2024 and December 31, 2023, the Company’s influence on Vitura is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 4 “ Investments ” for additional information. 19 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents There were no transfers between fair value categories during the periods presented. The following tables present information about the Company’s assets that are measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: As of March 31, 2024 Level 1 Level 2 Level 3 Total Other investments (i) $ — $ — $ 12,916 $ 12,916 As of December 31, 2023 Level 1 Level 2 Level 3 Total Other investments (i) $ — $ — $ 25,650 $ 25,650 (i) On June 14, 2021, the Company purchased an option to acquire 473,787 shares of Class A Common Stock of PharmaCann, a vertically integrated cannabis company in the United States, at an exercise price of $ 0.0001 per share, representing approximately 10.5 % of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $ 110,392 . As of March 31, 2024 and December 31, 2023, based on updated information provided by PharmaCann in the first quarter, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 6.3 % and 6.6 %. See Note 4 “ Investments .” There were no transfers between fair value categories during the periods presented. 11. Related Party Transactions (a) Cronos GrowCo The Company holds a variable interest in Cronos GrowCo through its ownership of 50 % of Cronos GrowCo’s common shares and senior secured debt in Cronos GrowCo. See Note 4 “ Investments ” for additional information. The Company made the following purchases of cannabis products from Cronos GrowCo: Three months ended March 31, 2024 2023 Cronos GrowCo – purchases $ 7,010 $ 7,466 As of March 31, 2024, and December 31, 2023, the Company had payables outstanding to Cronos GrowCo of $ 1,501 and $ 2,267 , respectively. During the third quarter of 2023, the Company, as supplier, entered into a cannabis germplasm supply agreement with Cronos GrowCo as buyer. During the three months ended March 31, 2024, the Company received $ 361 in relation to this agreement. Additionally, on August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into the GrowCo Facility. See Note 5 “ Loans Receivable, net ” for additional information. (b) Vendor Agreement In November 2022, the Company entered into an agreement with an external vendor whereby the vendor would provide certain manufacturing services to the Company. The vendor then subcontracted out a portion of those services to another company whose chief executive officer is an immediate family member of an executive of the Company. The Company purchased $ 833 of products and services under this subcontracted agreement for the three months ended March 31, 2023. The Company had $ 0 and $ 28 in outstanding payables related to the subcontracted agreement as of March 31, 2024 and December 31, 2023, respectively. In November 2023, the Company negotiated a direct contract with the related-party vendor. During the three months ended March 31, 2024, the Company purchased $ 772 of products and services under this agreement and had outstanding accounts payable related to the agreement of $ 134 and $ 11 as of March 31, 2024 and December 31, 2023, respectively. 20 Cronos Group Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) (In thousands of U.S. dollars, except share amounts) Table of Contents 12. Subsequent Events (a) Held-for-sale Classification of Peace Naturals Campus On November 27, 2023, the Company announced that Peace Naturals had entered into an agreement (the “Sale Agreement”) with Future Farmco Canada Inc. (“Future Farmco”) for the sale and leaseback of the Peace Naturals Campus. Pursuant to the terms of the Sale Agreement, Future Farmco has agreed to acquire the Peace Naturals Campus for an aggregate purchase price of C$ 23 million cash, subject to the terms and conditions set forth therein. At closing, the parties expect to enter into a lease agreement with respect to portions of the Peace Naturals Campus. In April 2024, the Company completed the activities required for the Peace Naturals Campus to be considered immediately available for sale, and therefore the underlying assets were reclassified to held-for-sale at that time. 21 Table of Contents